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Bispecific antibodies (BsAbs) are moving mainstream as therapeutics with currently two bispecific antibodies 
approved and about 30 in clinical development. The idea of using a BsAb as a therapeutic has been around for 
almost as long as its monospecific counterpart, however during this time over 40 MAbs were approved but only 
two BsAbs. One of the main reasons why BsAbs lag behind is that they are far more complex to produce.  
The co-expression of the two different heavy chains and two different light chains results in up to nine unwanted 
species in addition to the BsAb. Although a BsAb molecule can be made this way, it results in low yield and it is 
difficult to purify away the unwanted species. One solution to this pairing problem is to purify individual half-
antibodies, combine and finally purify the bispecific antibody. 
The presentation will discuss novel approaches to overcome the pairing challenge and enable production in a 
single cell. Heavy chain mispairing is prevented by the previously established knobs-into-holes technology, 
while novel mutations in the antibody heavy and light chain Fab region now facilitate orthogonal pairing of the 
light chains. 
In addition, strategies to screen for the best bispecific antibody will be discussed. This includes considerations 
for designing bispecifics to match the proposed mechanism of action and intended clinical application.  
